Media stories about iBio (NASDAQ:IBIO) have been trending positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. iBio earned a daily sentiment score of 0.29 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.8482497081417 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
iBio (IBIO) traded down $0.01 during mid-day trading on Friday, reaching $0.28. The company’s stock had a trading volume of 89,188 shares, compared to its average volume of 487,710. iBio has a 12-month low of $0.26 and a 12-month high of $0.56.
TRADEMARK VIOLATION WARNING: “Favorable Press Coverage Somewhat Unlikely to Impact iBio (NASDAQ:IBIO) Stock Price” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/11/positive-press-coverage-somewhat-unlikely-to-impact-ibio-ibio-share-price.html.
iBio, Inc is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company’s technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants.
Receive News & Ratings for iBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.